Thursday, 26 Apr 2018

You are here

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

Psoriasis children were likely to be obese (2.9% vs 1.5%; P < .001). They were also significantly more likely to develop each of the studied comorbidities than those without psoriasis (P < .01).

In nonobese children, psoriasis was associated with a 40% to 75% risk of comorbidity:

  • Hyperlipidemia - HR, 1.42; 95% CI, 1.25-1.62
  • HTN - HR, 1.64; 95% CI, 1.40-1.93
  • Diabetes - HR, 1.58; 95% CI, 1.27-1.95
  • Metabolic syndrome -  HR, 1.62; 95% CI, 1.13-2.33
  • Polycystic ovarian syndrome - HR, 1.49; 95% CI, 1.18-1.88
  • Nonalcoholic liver disease (HR, 1.76; 95% CI, 1.16-2.65
  • Elevated liver enzymes - HR, 1.46; 95% CI, 1.27-1.67

 

Obesity was a strong risk factor for development of comorbidity, even without psoriasis (HR ranging from 2.26 to 18.11).

Children with psoriasis are at greater risk of developing obesity, hyperlipidemia, hypertension, diabetes, metabolic syndrome, polycystic ovarian syndrome, nonalcoholic liver disease, and elevated liver function enzyme levels than children without psoriasis.

However, obesity is a much stronger risk factor for comorbidity in children with psoriasis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept

The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients. 

PRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy

Rheumatoid arthritis patients who were younger and who had lower body mass index, Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.